122 related articles for article (PubMed ID: 38905817)
1. Cost-Effectiveness of Dolutegravir Compared With Efavirenz for Prevention of Perinatal Transmission in Women Presenting With HIV in Late Pregnancy in Uganda.
Nuwamanya E; Nassiwa SC; Kuznik A; Waitt C; Malaba T; Myer L; Colbers A; Read J; Wang D; Lamorde M
Value Health Reg Issues; 2024 Jun; 44():101017. PubMed ID: 38905817
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia.
Belay YB; Ali EE; Chung KY; Gebretekle GB; Sander B
Pharmacoecon Open; 2021 Dec; 5(4):655-664. PubMed ID: 34133017
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India.
Zheng A; Kumarasamy N; Huang M; Paltiel AD; Mayer KH; Rewari BB; Walensky RP; Freedberg KA
J Int AIDS Soc; 2018 Mar; 21(3):e25085. PubMed ID: 29603882
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
Isah A; Chukwu PO; Abba A; Igboeli NU; Ebere A; Omotola OF; Alozie FA; Ekwunife OI; Adibe MO
Afr Health Sci; 2023 Mar; 23(1):157-169. PubMed ID: 37545946
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
9. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
10. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.
Punekar YS; Guo N; Tremblay G; Piercy J; Holbrook T; Young B
Cost Eff Resour Alloc; 2019; 17():26. PubMed ID: 31827410
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
[TBL] [Abstract][Full Text] [Related]
12. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV.
Mahale PR; Patel BS; Kasmani N
Cureus; 2023 Jun; 15(6):e40139. PubMed ID: 37435267
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
15. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
16. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial.
Jamieson L; Serenata C; Makhubele L; Sokhela S; Mashabane N; Akpomiemie G; Johnson LF; Venter WDF; Meyer-Rath G
AIDS; 2021 Dec; 35(Suppl 2):S173-S182. PubMed ID: 34848584
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.
Kuznik A; Lamorde M; Hermans S; Castelnuovo B; Auerbach B; Semeere A; Sempa J; Ssennono M; Ssewankambo F; Manabe YC
Bull World Health Organ; 2012 Aug; 90(8):595-603. PubMed ID: 22893743
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
[No Abstract] [Full Text] [Related]
20. Weight gain during pregnancy among women initiating dolutegravir in Botswana.
Caniglia EC; Shapiro R; Diseko M; Wylie BJ; Zera C; Davey S; Isaacson A; Mayondi G; Mabuta J; Luckett R; Makhema J; Mmalane M; Lockman S; Zash R
EClinicalMedicine; 2020 Dec; 29-30():100615. PubMed ID: 33437946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
